Excelsior Biopharma (6496) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Excelsior Biopharma (6496) has a cash flow conversion efficiency ratio of -0.028x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-22.21 Million ≈ $-699.64K USD) by net assets (NT$804.23 Million ≈ $25.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Excelsior Biopharma stock valuation for the company's overall valuation and market capitalisation.
Excelsior Biopharma - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Excelsior Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Excelsior Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Excelsior Biopharma ranked by their cash flow conversion efficiency. Explore Excelsior Biopharma (6496) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aeries Technology Inc.
NASDAQ:AERT
|
-1.835x |
|
Iktinos Hellas S.A. Greek Marble Industry Technical and Touristic Company
AT:IKTIN
|
-0.030x |
|
Mega Perintis Tbk PT
JK:ZONE
|
-0.109x |
|
GenoFocus Inc
KQ:187420
|
-0.015x |
|
DLP Resources Inc
V:DLP
|
-0.246x |
|
Hunt Electronic Co Ltd
TWO:3297
|
0.082x |
|
Yooshin Engineering Corporation
KQ:054930
|
0.157x |
|
Reino Capital SA
WAR:RNC
|
0.064x |
Annual Cash Flow Conversion Efficiency for Excelsior Biopharma (2017–2025)
The table below shows the annual cash flow conversion efficiency of Excelsior Biopharma from 2017 to 2025. View Excelsior Biopharma (6496) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$804.23 Million ≈ $25.34 Million |
NT$-138.72 Million ≈ $-4.37 Million |
-0.172x | -71.36% |
| 2024-12-31 | NT$991.45 Million ≈ $31.24 Million |
NT$-99.80 Million ≈ $-3.14 Million |
-0.101x | +17.50% |
| 2023-12-31 | NT$1.10 Billion ≈ $34.80 Million |
NT$-134.75 Million ≈ $-4.25 Million |
-0.122x | -2785.29% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.04 Million |
NT$5.49 Million ≈ $172.84K |
0.005x | -89.99% |
| 2021-12-31 | NT$1.23 Billion ≈ $38.76 Million |
NT$55.82 Million ≈ $1.76 Million |
0.045x | -88.82% |
| 2020-12-31 | NT$1.28 Billion ≈ $40.42 Million |
NT$520.81 Million ≈ $16.41 Million |
0.406x | +400.08% |
| 2019-12-31 | NT$1.25 Billion ≈ $39.53 Million |
NT$-169.74 Million ≈ $-5.35 Million |
-0.135x | -246.36% |
| 2018-12-31 | NT$1.37 Billion ≈ $43.26 Million |
NT$126.92 Million ≈ $4.00 Million |
0.092x | -64.57% |
| 2017-12-31 | NT$1.34 Billion ≈ $42.21 Million |
NT$349.47 Million ≈ $11.01 Million |
0.261x | -- |
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more